Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research by O. Pelkonen et al.
1 
 
 
Chemical exposure and infant leukaemia: development of an adverse outcome pathway 
(AOP) for aetiology and risk assessment research1 
Olavi Pelkonen1, Andrea Terron2, Antonio F. Hernandez3, Pablo Menendez4, Susanne 
Hougaard Bennekou5, on behalf of the EFSA WG EPI1 and its other members6 
1Department of Pharmacology and Toxicology and Clinical Research Unit, University of 
Oulu, Finland 
2European Food Safety Authority (EFSA), Parma, Italy 
3University of Granada School of Medicine, Granada, Spain 
4a. Josep Carreras Leukemia Research Institute and Department of Biomedicine, School of 
Medicine, University of Barcelona; b. Instituciò Catalana de Recerca i Estudis Avançats 
(ICREA), Barcelona, and c. Centro de Investigación Biomédica en Red en Cancer del ISCIII 
(CIBERONC), Spain 
5The Danish EPA, Copenhagen, Denmark 
6Karine Angeli, ANSES, France 
Ellen Fritsche, IUF, Leibniz Research Institute for Environmental Medicine, Dusseldorf, 
Germany 
Marcel Leist, University of Konstanz, Germany 
Alberto Mantovani, Istituto Superiore di Sanità, Rome, Italy 
Anna Price, EU JRC, Ispra, Italy 
Barbara Viviani, University of Milan, Italy 
 
Contact: Olavi Pelkonen, Pharmacology and Toxicology, Aapistie 5 B (POB5000), FIN-
90014 University of Oulu, Finland (olavi.pelkonen@oulu.fi) 
 
 
Acknowledgements: We thank Dr. Kenneth McCreath for critical reading and helping with 
English editing and.Marcella de Maglie for figure drawing. P.M is supported by the European 
Research Council (CoG-2014-646903), the Spanish Ministry of Economy-Competitiveness 
(SAF-SAF2013-43065), the Asociación Española Contra el Cáncer, the ISCIII/FEDER 
(PI14/01191-PI13/00168), the Obra Social La Caixa-Fundaciò Josep Carreras, the Inocente-
Inocente Foundation and Generalitat de Catalunya. P.M is investigator of the Spanish Cell 
Therapy cooperative network (TERCEL).  
 
  
                                                 
1 this article is based on the activity of the EFSA Working Group on Investigation into experimental toxicological 
properties of plant protection products having a potential link to Parkinson’s disease and childhood leukaemia. 
The Scientific Opinion is published in the EFSA Journal; EFSA J. 2017; 15(3):4691, 325 pp. 
doi:10.2903/j.efsa.2017.4691. 
 
 
Manuscript Click here to download Manuscript Pelkonen et al - AOP Infant
Leukaemia - FINAL (clean).docx
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Abstract 
Infant leukaemia (<1 year old) is a rare disease of an in utero origin at an early phase of foetal 
development. Rearrangements of the mixed-lineage leukemia (MLL) gene producing 
abnormal fusion proteins are the most frequent genetic/molecular findings in infant B cell-
acute lymphoblastic leukaemia (ALL). In small epidemiological studies, mother/foetus 
exposures to some chemicals including pesticides have been associated with infant leukaemia; 
however, the strength of evidence and power of these studies are weak at best. Experimental 
in vitro or in vivo models do not sufficiently recapitulate the human disease and regulatory 
toxicology studies are unlikely to capture this kind of hazard. Here we develop an adverse 
outcome pathway (AOP) based substantially on an analogous disease – secondary acute 
leukaemia caused by the topoisomerase II (topo II) poison etoposide – and on cellular and 
animal models. The hallmark of the AOP is the formation of MLL gene rearrangements via 
topo II poisoning, leading to fusion genes and ultimately acute leukaemia by global 
(epi)genetic dysregulation. The AOP condenses molecular, pathological, regulatory and 
clinical knowledge in a pragmatic, transparent and weight of evidence-based framework. This 
facilitates the interpretation and integration of epidemiological studies in the process of risk 
assessment by defining the biologically plausible causative mechanism(s). The AOP 
identified important gaps in the knowledge relevant to aetiology and risk assessment, 
including the specific embryonic target cell during the short and spatially-restricted period of 
susceptibility, and the role of (epi)genetic features modifying the initiation and progression of 
the disease. Furthermore, the suggested AOP informs on a potential Integrated Approach to 
Testing and Assessment (IATA) to address the risk caused by environmental chemicals in the 
future.  
  
 
Keywords: infant leukaemia; MLL fusion products; risk assessment; etoposide; DNA 
topoisomerase II 
Abbreviations: ALL, acute lymphoblastic leukaemia; HSPC, hematopoietic stem and 
progenitor cell; IATA, Integrated Approach to Testing and Assessment; MLL, mixed-lineage 
or myeloid/lymphoid leukaemia (gene); MLL-r, rearrangements of MLL gene; t-AL, therapy-
associated acute leukaemia; topo II, DNA topoisomerase II.  
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INTRODUCTION 
Do chemicals in general and pesticides in particular cause leukaemia in early childhood? That 
is the question raised by epidemiological investigations that, by their nature, are necessarily 
challenging and currently yield only “weak signals” of possible associations (Hernandez and 
Menendez, 2015). Although acute leukaemia is the most common cancer diagnosed in 
children aged less than 15 years, it is actually a phenotypically- and genetically-
heterogeneous disease of immature hematopoietic stem and progenitor cells (HSPCs). 
Another important challenge to epidemiological studies is the complexity of delineating infant 
leukaemia from childhood leukaemia, as they represent a collection of aetiologically and 
mechanistically different diseases with variable natural histories and outcomes. In particular, 
infant leukaemia is an early-onset, rapidly developing and prognostically dismal form of 
paediatric leukaemia, which can also be considered as a developmental disease of immature 
HSPCs.  
 
The low incidence of infant cancer represents a challenge for epidemiological correlative 
studies. The potential role of in utero exposure to environmental chemicals, including 
pesticides, in initiating paediatric leukaemia was originally suspected on the basis of 
epidemiological studies ((Ntzani et al., 2012; Hernandez and Menendez, 2015). The 
association between prenatal exposure (via occupational exposure of the parents) and 
pediatric leukaemia was observed both for ALL and acute myeloid leukaemia (AML), but 
recognising the considerable uncertainty in regard to the assessment of pesticide exposure. 
Besides an association with the generic term ’pesticides’, the data did not allow to conclude 
about a single pesticide, or a specific pesticide group, associated with a significant risk of 
pediatric leukaemia. Also, almost all the available studies on the topic included both infant 
leukaemia and childhood leukaemia in the same diagnosis. Because only very few studies 
examined the risk of pesticide exposure with infant leukaemia as a separate entity,(Pombo-de-
Oliveira et al., 2006; Ferreira et al., 2013), data thus far do not allow any firm conclusions to 
be drawn.  
 
However, there is a form of human acute leukaemia caused by certain anticancer drugs that 
can be divided into two well-defined groups according to whether the patient has received 
alkylating agents or drugs binding to the enzyme DNA-topoisomerase, such as 
epipodophyllotoxins and anthracyclines (Mistry et al., 2005; Felix et al., 2006; Leone et al., 
2007). This is the so-called treatment-associated acute leukaemia, whereby anticancer agents 
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have been considered to play an aetiological role in promoting the driver genetic oncogenic 
events (Cowell and Austin, 2012; Ezoe, 2012; Pendleton et al., 2014; Gole and Wiesmuller, 
2015). The most well-known chemotherapeutical agent is etoposide (an epipodophyllotoxin), 
which can induce the formation of a fusion gene as a result of a chromosomal translocation 
involving the mixed-lineage leukaemia (MLL, KMT2A ) gene and other partner genes through 
topoisomerase II (topo II) “poisoning”.  
 
The Adverse Outcome Pathway (AOP) is a conceptual framework linking the Molecular 
Initiating Event (MIE) to a final Adverse Outcome (AO). It provides a basis for multiple-level 
data integration by defining the intermediate essential Key Events (KEs) that link the MIE to 
the AO, and providing a scientifically firm rationale for the KE relationship (KER) (OECD, 
2013). In this review, a panel of experts working on a European Food and Safety Authority 
(EFSA) mandate surveyed the scientific background, assisted by a systematic literature 
review (Choi et al 2016), to build a biologically plausible and experimentally supported AOP 
linking in utero poisoning of topo II enzyme with the ultimate AO “infant leukaemia” (see 
also https://aopwiki.org/aops/202). Finally, we outline potential uses of this AOP for 
identifying future research needs and for regulatory decisions regarding chemicals with 
appropriate experimental findings. 
 
What is infant leukaemia? 
B cell-ALL is the most frequent cancer in children. Infant leukaemia is a rare haematological 
disease with an incidence of 1 in 106 newborns, accounting for 10% of all B cell-ALLs in 
children younger than 15 years, manifesting soon after birth (<1 year) and displaying an 
intermediate prognosis except for some cytogenetic subgroups such as MLL-rearranged 
(MLL-r) B cell-ALL, which remains an outlier high-risk group having a poor prognosis 
(Sanjuan-Pla et al., 2015). Compared with the more frequent childhood leukaemias, infant 
leukaemia shows distinct features (see Table 1 for a more comprehensive comparison):  
- An early neonatal manifestation suggests an in utero initiation as an ‘intrauterine 
developmental disease’ (Greaves, 2015; Sanjuan-Pla et al., 2015);  
- Rearrangements of the MLL gene on the q23 band of chromosome 11 as the hallmark 
genetic abnormality (Joannides and Grimwade, 2010). 
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- However, MLL is not the only translocation gene2. Whereas about 60–80% of infant ALL 
carry an MLL-r (Sam et al., 2012; Jansen et al., 2007), for infant acute myeloid leukaemia 
(AML) the percentage of MLL- r is lower than 40%;  
- The MLL-r occurs at an early stage of development, with the target cells (still unidentified) 
being likely the HSPCs in foetal liver and/or pre-haematopoietic mesodermal foetal 
precursors (Bueno et al., 2009; Menendez et al., 2009);  
- Infant MLL-r leukaemia has the least number of somatic mutations among all the sequenced 
cancers (1.3 vs 6.5/case; Andersson et al., 2015; Dobbins et al., 2013), pointing to the lack of 
a “second hit” assumed in the classic carcinogenesis paradigm.  
 
The overall scientific evidence, including the stable genome of patients, suggests that infant 
leukaemia originates from one “big-hit” occurring during a critical developmental window of 
HSPC vulnerability (Andersson et al., 2013; Greaves, 2015). In contrast to the “two-hit” 
model of the adult and childhood leukaemias, infant leukaemia is a developmental disorder 
where the differentiation arrest and clonal expansion are a direct consequence of in utero MLL 
translocation in target HSPCs. 
 
Secondary treatment-related acute leukaemia: a model for infant leukaemia? 
Secondary acute leukaemia carrying MLL-r is an adverse effect observed in patients treated 
with etoposide and a few other anticancer agents. Characteristics of the disease are in many 
ways analogous to those in infant leukaemia (Joannides et al., 2010, 2011) (Table 1). This so-
called therapy-associated acute leukaemia (t-AL) in adults is characterised by its short 
latency, <2 years between the treatment of the primary malignancy with epipodophyllotoxins 
and the clinical diagnosis of the secondary disease, and by the poor prognosis (Cowell and 
Austin, 2012; Ezoe, 2012; Pendleton et al., 2014). It is recognised that the MLL-r fusion genes 
are caused by etoposide, other epipodophyllotoxins or anthracyclines, because MLL-r have 
not been detected in bone marrow samples banked before the initiation of the treatment for 
the first malignancy (Cowell and Austin, 2012; Pendleton et al., 2014). Overall, the evidence 
supporting the causal relationship between etoposide-induced topo II inhibition and further 
formation of cleavage complexes leading to MLL-r is strong and could be regarded as ‘beyond 
reasonable doubt’. Also, the breakpoints in MLL or partner genes fall within a few base pairs 
                                                 
2 Even if MLL is not present in 100% of infant leukaemias, the ‘MLL-rearranged (MLL-r) infant leukaemia’, 
especially MLL-r B-ALL, is taken here as a model for the disease principally because of the quantity of scientific 
evidence. 
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of a drug-induced enzyme-mediated DNA cleavage site (Cowell and Austin, 2012, Pendleton 
et al., 2014; Gole and Wiesmuller, 2015). All the above disease characteristics, MLL-r, short 
latency and poor prognosis, strongly suggest that infant leukaemia and treatment-related 
leukaemia are sufficiently similar to allow for inferences to be made regarding tentative 
aetiological factors, molecular events and disease progression and manifestation. Thus, 
etoposide can be considered as a model chemical for DNA topo II inhibition and MLL-r and it 
was used here as a tool compound to empirically support the linkage between MIE and AO in 
the AOP. 
 
Etoposide 
There is abundant evidence on the interaction of etoposide with topo II enzymes, resulting in 
further chromosomal translocations (in particular MLL-r) at the cell culture level and in 
relation to treatment-related leukaemia (Cowell and Austin, 2012; Ezoe, 2012; Pendleton and 
Osheroff, 2014; Gole and Wiesmuller, 2015). Etoposide can induce MLL-r in different cell 
types. Interestingly, embryonic stem cells and their hematopoietic derivatives are much more 
sensitive than cord blood-derived CD34+ cells to etoposide induced MLL-r. In addition, 
undifferentiated human embryonic stem cells (hESCs) were concurrently predisposed to acute 
cell death (Bueno et al., 2009). The effects of etoposide in various model systems will be 
described in detail in the description of the developed AOP.  
 
There should be some information about the concentration-response relationships of the 
selected tool chemical in the development of the AOP. Molecular dose-response modelling of 
etoposide-induced DNA damage response, based on comprehensive in vitro high content 
imaging in the HT1080 cell model, was developed by Li et al. (2014). The model was based 
on the hypothesis that cells are capable of clearing low-level DNA damage with existing 
repair capacity; however, when the number of double strand breaks (DSBs) exceeds a 
threshold value, ataxia telangiectasia mutated (ATM) is recruited and becomes fully activated 
through a reversible mechanism, leading to elevated repair capacity as a result of 
phosphorylation (activation) of several target proteins, including p53 and other tumour 
suppressor proteins. The model was able to quantitatively capture the dose-response 
relationships of a number of markers observed with etoposide. Especially interesting are the 
dose-response relationships for activation of p53 and the formation of micronuclei in the 
target cell model, which indicate point-of-departure concentrations of etoposide in the range 
of 0.01 to 0.1 µM (Li et al., 2014). This range is in agreement with the finding that in human 
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foetal liver CD34+ cells an increase in DSBs was observed at a concentration of 0.14 µM 
(Bueno et al., 2009) and MLL-r were detectable by FISH or flow cytometry at higher 
concentrations (Moneypenny et al., 2006).  
 
The general structure of the AOP 
The AOP concept has been developed to incorporate the available information into a wider 
context, and to integrate various pieces of scientific information into a structurally coherent 
and biologically plausible framework of identifiable, not necessarily fully developed, essential 
key events that comprise linear and sequential processes in the way from the MIE through a 
variable number of intermediary steps, that is, key events, to the AO. Information to build the 
AOP may come from any type of scientific study and span various levels of biological 
organization, from molecular to organism levels. This chain of biological events is considered 
relevant for risk assessment. The AOP is not the final goal in itself; instead, it could serve 
several purposes, for example, identification of crucial targets and processes and their 
employment in the development of novel tests and screening systems, and, ultimately, the 
elaboration of prioritisation strategies and research programs (OECD, 2012; Vinken, 2013). 
Although the AOP as a concept is similar to the mode of action, since both take into account 
mechanistic information, one major difference is that a mode of action focuses on the details 
specific to a particular chemical (i.e., toxicokinetic and toxicodynamic information), whereas 
the AOPs represent the chemical-agnostic portions of toxicity pathways (i.e., toxicodynamic 
information) to increase the generalisability of their application from early key events to overt 
toxicity (Edwards et al., 2016). 
 
The AOP for Infant Leukaemia 
The final structure of the developed AOP is presented in Fig 1 and elaborated in detail in the 
subsequent sections. The first key event, the MIE, is the in utero DNA topo II inhibition, 
‘poisoning’, and further stabilisation of the normally transient reaction DNA-topo II 
intermediate in which the enzyme is covalently bound to DNA. If topo II poisons target the 
MLL breakpoint cluster region, the MLL gene can be cleaved via DNA DSBs. If the DNA 
lesions are not correctly repaired by the error-prone non-homologous end joining (NHEJ) 
repair system, DSBs accumulate. Thus, the MLL gene can be rearranged with a number of 
other genes that have been simultaneously cleaved, resulting in the formation of fusion genes, 
which represent the second key event. Molecular and cellular processes of the first key event 
relationship (KER1) have been clarified at least on a general level. The product of the fusion 
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gene encompasses many preserved and acquired functions of the fusion partners associated 
with differentiation block of HSPCs and expansion of clones expressing the fusion product 
(KER2). Originally an additional (third) key event, differentiation block and clonal expansion, 
was envisaged, but ultimately (at least for the time being), we decided that the information is 
in effect contained in the fusion protein and, finally, the process (KER2) from the rearranged 
fusion gene leads to the manifest leukaemia (the third key event or adverse outcome, AO). 
The precise molecular and cellular processes behind KER2 remain incompletely understood, 
but changes in gene activation and repression as well as in epigenetic regulation in a 
hypothetical “permissible” cellular environment, restricted in time and space, likely play a 
decisive role (Greaves, 2015; Sanjuan-Pla et al., 2015).  
 
In summary, current scientific evidence, including the stable genome of the patients, suggests 
that infant leukaemia originates from one “big-hit” occurring during a critical developmental 
window of stem cell vulnerability (Andersson et al., 2013; Greaves, 2015). Therefore, the 
totality of evidence suggests the essential role of the formation of MLL-AF4 (or other partner) 
fusion gene (and product) in causing pleiotropic effects in the affected cell, which is then 
directed to the obligatory pathway to the adverse outcome of infant leukaemia (see KER2).  
 
The AOP is presented in detail in the following sections. As becomes evident, the proposed 
AOP is supported by convincing inferential evidence using etoposide as a tool compound to 
empirically support the linkage between the proposed MIE and the AO.  
 
Molecular Initiating Event (MIE): In utero exposure to DNA topoisomerase II “poisons” 
DNA topoisomerases are ubiquitous enzymes that control the integrity of double-stranded 
DNA. They are thus key enzymes at all levels of living organisms. While type II 
topoisomerases are essential for the survival of proliferating cells, they can also contribute 
significantly to genotoxic effects via accumulation of DNA DSBs that, if not leading to cell 
death, may result in chromosomal translocations in the surviving cell population (McClendon 
et al., 2007). 
 
Topo II enzymes have several crucial functions in DNA replication, transcription, repair and 
chromatin remodelling, maintaining DNA integrity and topology. Because the enzyme 
functions by passing an intact double helix through a transient double-stranded break, any 
disturbance in its function, for example by chemical inhibitors, could have a profound effect 
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on genomic stability, resulting in activation of DNA damage response, initiation of apoptosis 
and ultimate cell death, or on gene and chromosomal damage and its repair. A DSB and error-
prone NHEJ DNA repair mechanism may lead to gene rearrangements, chromosomal 
translocations and consequently gene fusion (see Fig 1). Characteristics of topo II enzymes 
and their functions and inhibitions have been extensively reviewed (Cowell and Austin, 2012; 
Pendleton et al., 2014; Ketron and Osheroff, 2014). 
 
Compounds that increase the rate of DNA cleavage and decrease the rate of DNA religation 
by topo II enzyme are often referred to as topo II ‘poisons’ (Nitiss, 2009). Such “poisons” 
disturb the normal enzyme function and cause a ‘hanging DSB’ at a specified DNA sequence, 
thus creating the potential for fusion gene formation. The above description of the MIE is 
significant because there are 3 different types of topo II inhibitors, including competitive 
inhibitors that prevent the function of the enzyme and cause cell death, and interfacial and 
covalent inhibitors that may cause–depending on the situation–other effects on DNA damage 
response such as chromosomal rearrangements (Pendleton et al., 2014; Lu et al., 2015). A 
further prerequisite for the specific outcome, that is, creation of chromosomal rearrangement, 
is that topo II poisoning occurs in an especially vulnerable and correct “hot spot” in the MLL 
locus, in the specific target cell vulnerable to transformation (Gole and Wiesmuller, 2015).  
 
How the MIE is measured 
Measurement of the inhibition of topo II enzymes is complicated by the existence of different 
molecular mechanisms (see above). However, some assays are used to screen topo II 
“poisons”, including cell-free decatenation assay (Schroeter et al., 2015). The most important 
mode, the cleavage activity of topo II, can be studied in vitro using a human recombinant 
enzyme and an appropriate double-stranded plasmid as a target to quantitate DSBs (Fortune 
and Osheroff, 1998). Cleavage can also be indirectly detected by measuring the outcomes it 
elicits with regards to indicators of DNA damage response, such as ATM activity, p53 
expression, γH2AX (phosphorylated form of the histone H2AX) or the Comet assay (Li et al., 
2014, Schroeter et al., 2015, Castano et al., 2016). 
 
How DNA topoisomerase II inhibition leads to in utero MLL chromosomal 
translocation: Key Event Relationship 1 (KER1) 
Formation of the fusion gene 
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Certain topo II poisons stabilise (and trap) the intermediate “cleavage complex”, preventing 
the religation with appropriate DNA strands. Covalent DNA end-bound topo II protein is 
digested and a hanging end is created. The same process occurs in the translocation partner 
gene. The hanging ends of both genes are processed and two heterologous ends are 
subsequently joined by NHEJ (Cowell and Austin, 2012). There is evidence that this 
inappropriate joining of ‘hanging ends’ occurs in the same transcriptional factory (hub), and 
the result is a fusion gene and ultimately a chimeric protein product (Cowell & Austin, 2012; 
Pendleton et al., 2014; Sanjuan-Pla et al., 2015). The first part of this description has not been 
shown in the putative target cell, which is still not unequivocally identified; but for the second 
part, there is ample evidence of formation of MLL-AF4 fusion product as a result of a very 
early chromosomal translocation and re-joining. It is notable that the simultaneous induction 
of specific DSBs in introns of the MLL gene and two different translocation partners (AF4 
and AF9) by engineered nucleases in human HSPCs resulted in specific ‘patient-like’ 
chromosomal translocations (Breese et al., 2016). 
 
Embryo-foetal origin of a fusion gene 
The occurrence of MLL-r at a very early foetal development stage is highly probable on the 
basis of neonatal blood spot analysis and by the near 100% concordance rate of infant 
leukaemia in monozygotic twins (Ford et al., 1993; Gale et al., 1997).  
 
Experimentally, the induction of DNA breaks and MLL-r by etoposide and some 
bioflavonoids has been demonstrated in human foetal liver HSPCs, hESCs and in cord blood 
mononuclear cells (Ishii et al., 2002; Blanco et al., 2004; Moneypenny et al., 2006; Bueno et 
al., 2009; Menendez et al., 2009), which clearly shows that topo II-associated MLL-r 
rearrangements are produced in prenatal and neonatal human cells.   
 
Etoposide treatment in mice at day 13.5 of pregnancy induces mll breakage in foetal liver 
HSPCs in utero, but MLL-r fusion mRNAs were detected only in mice that were defective in 
the DNA damage response (ATM-knockout mice). A fusion gene analogous to MLL-AF4 was 
not detectable in wild-type mice. A statistically significant increase (about 6-fold) in DSBs in 
the mll gene of isolated foetal liver HSPCs was observed after a single dose of 1 mg/kg to 
pregnant mice. A clear activation of DNA damage response was observed at the dose of 10 
mg/kg (Nanya et al., 2016).  
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In utero MLL chromosomal translocation: Key Event 1 (KE1) 
Fusion genes and their products 
Rearrangements of the MLL gene, located on chromosome 11 (11q23), are the genetic 
hallmark of most infant leukaemias (Meyer et al., 2013; Sanjuan-Pla et al., 2015). The MLL 
gene spans a chromosomal fragile site (that is, a region of the genome susceptible to breakage 
under conditions of replication stress), and chemical interference with topo II activity may 
promote fragile site instability. More than 95% of the MLL-r occur within a ~7.3 kb 
breakpoint cluster region (bcr) that is distributed in two clusters, with breaks from t-AL and 
infant leukaemia being located at the telomeric part of the MLL bcr (Gole and Wiesmuller, 
2015). MLL breakpoint site sequences in the t-AL fall within a few base pairs of an etoposide-
induced enzyme-mediated DNA cleavage site (Cowell and Austin, 2012; Meyer et al., 2013). 
Although rearrangements associated with infant leukaemias are often more complex than 
those observed in t-AL, many are nevertheless associated with stable topo II-mediated DNA 
cleaved sites. While many of these findings are indirect regarding infant leukaemia, they are 
nonetheless rather persuasive in this respect. 
 
DNA breakage within the MLL gene can lead to rearrangement with over 90 partner genes, 
leading to many translocations and fusion partners (Meyer et al., 2013). In principle, all MLL 
fusion genes are potential initiating drivers, although clinical studies have shown 
preponderance with infant leukaemia for only a few of these rearrangements. For infants 
diagnosed with ALL, approximately 60–80% carry an MLL rearrangement (Sam et al., 2012; 
Jansen et al., 2007), with principal fusion partners being AF4 (41%), ENL (18%), AF9 (11%) 
or another partner gene (10%). In particular, the fusion gene MLL-AF4 shows a specific and 
consistent relationship with the disease (Menendez et al., 2009); however, it has been difficult 
to reproduce an overt disease resulting from this rearrangement in animal models (see later 
sections). 
 
Menendez et al. (2009) showed that MLL-AF4 fusion gene is present and expressed in bone 
marrow mesenchymal stem cells in infant patients with t(4;11) B cell-ALL. However, other 
paediatric B cell-ALL-specific translocations/gene fusions were never found in this cell 
population. This suggests that the origin of the fusion gene in infant B cell-ALL is likely 
prehaematopoietic. Consequently, the target cell for transformation may be an early 
prehaematopoietic mesodermal precursor, a haematopoietic stem cell or a haematopoietic 
progenitor cell residing mainly in the liver (Greaves, 2015; Sanjuan-Pla et al., 2015). 
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Fusion proteins and their functions 
The MLL gene encodes a lysine-specific histone methyltransferase 2A, a protein homologous 
to the Drosophila trithorax gene, which has important functions in embryogenesis and 
haematopoiesis (Ernest et al., 2004, Hess et al., 1997). MLL protein (complexed with a large 
number of other protein factors) serves as an epigenetic transcriptional activator or repressor 
via its binding to promoter regions of active genes, marking these regions by covalent histone 
modifications (Sanjuan-Pla et al., 2015). Chromosomal translocations affecting the MLL gene 
result in fusion genes that destroy the intrinsic control mechanisms of the MLL protein. The 
resulting aberrant functions involve promoter hyperactivation and reacquisition of stem cell 
features (Marschalek, 2010; Sanjuan-Pla et al., 2015). 
 
How the KE1 is measured 
The presence and structure of a fusion gene can be identified using PCR or related techniques. 
Mapping of cleavage sites in the gene requires genomic DNA. In cells or tissues, the detection 
of a fusion gene is possible by suitable immunofluorescence techniques. Assays measuring 
chromosomal aberrations, micronuclei or DNA chromosome damage (e.g., Comet assay) may 
indirectly identify the KE through its consequences in experimental systems in vitro and in 
vivo; the degree of accuracy of such identification cannot be evaluated presently. 
Comprehensive genomic tool platforms have been developed to screen genomic changes in 
leukaemic diseases (McKerrell et al., 2016). 
 
How in utero MLL-r leads to infant leukaemia: Key Event Relationship 2 (KER2) 
Propagation of a leukaemic cell clone requires both blockage of differentiation to more 
mature cells and ability to expand in an uncontrolled manner. It is probable that the potential 
of both differentiation blockage and clonal expansion are inherent properties of the MLL-r 
fusion product, based on the preservation of some original functions (even if in a modified 
form) and on the gain of other functions as a result of sequences from the new fusion partner 
gene (Marschalek, 2010; Sanjuan-Pla et al., 2015). As the formation of the MLL-r fusion 
genes and their protein products are intimately involved both in the blocked differentiation of 
HSPCs and the expansion of the fusion gene-carrying clone, it is believed that the fusion gene 
product blocks cell differentiation by inhibiting the normal transcriptional programs and 
recruiting repressor molecules such as histone modifying enzymes (Greaves, 2002; Teitell and 
Pandolfi, 2009). Furthermore, the fusion gene product activates other key target genes, which 
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ultimately leads to the propagation of transformed cell lines without normal restrictions 
(Greaves, 2015; Sanjuan-Pla et al., 2015).  
 
Molecular mechanisms 
The MLL gene is the most common translocation gene identified in infant leukaemia. The N-
terminal part of MLL becomes fused in-frame to one of a large number of fusion partners, but 
in most cases, this fusion occurs between the N-terminal MLL and AF4, AF6, AF9, AF10, or 
ENL (Krivtsov and Armstrong, 2007; Meyer et al., 2013). The N-terminal MLL remaining in 
the fusion gene contains a motif for DNA-binding with target genes controlled by MLL 
irrespective of the normal location of the C-terminal partner (Farooq et al., 2016).  
 
The role of the fusion partners in the process of leukaemogenesis has not been completely 
elucidated. Table 2 lists some of the salient functional features of the most frequent fusion 
partners of the MLL gene. Normally, all of them participate in chromatin modifying 
complexes, for example, super elongation complex, which act on the transcriptional 
regulation of target genes such as homeobox A (HOXA) cluster genes or myeloid ectopic viral 
integration site 1 homolog (MEIS1). This highly regulated process is disturbed by the 
presence of MLL fusion proteins and it seems probable that different fusion partners are 
distinct entities with variable modulatory effect on signalling pathways in leukaemic cells 
(Marschalek, 2010).  
 
Many fusion proteins have been shown to recruit disruptor of telomeric silencing 1-like 
(DOT1L or officially KMT4, a histone methyltransferase that methylates lysine 79 located 
within the globular domain of histone H3, H3K79) to the promoters of MLL target genes. This 
recruitment seems to be a common feature of many oncogenic MLL fusion proteins and 
results in abnormal H3K79 methylation and overexpression of several MLL target genes, 
such as HOXA genes coding for transcription factors involved in body patterning and 
haematopoiesis (Chen and Armstrong, 2015). Although DOT1L is not genetically altered in 
the disease per se, its mislocated enzymatic activity is a direct consequence of the 
chromosomal translocation. Thus, DOT1L has been proposed to be a catalytic driver of 
leukaemogenesis (Chen and Armstrong, 2015; Kerry et al., 2017). The enzymatic activity of 
DOT1L is critical to the occurrence of MLL because methyltransferase-deficient DOT1L is 
capable of suppressing growth of MLL-rearranged cells. A small-molecule inhibitor of 
DOT1L inhibits cellular H3K79 methylation, blocks leukaemogenic gene expression, and 
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selectively kills cultured cells bearing MLL translocations (Chen and Armstrong, 2015). One 
of the target genes of DOT1L is BCL-2, belonging to a family of anti-apoptotic genes, which 
maintains the survival of the MLL-rearranged cells (Benito et al., 2015; Godfrey et al., 2017). 
Expression of BCL-2 is high in human MLL-AF4 leukaemia cells from a large number of 
patients and BCL2 inhibition with specific antagonists may make MLL-r infant leukaemia 
sensitive to current treatment. Fig 2 provides a schematic representation of potential 
molecular pathways. 
 
Potential significance of secondary oncogenic events 
Recurrent activating mutations in the components of the phosphoinositide 3-kinase (PI3K)-
RAS signalling pathway have been detected in almost 50% of the tested MLL-r ALLs 
(Andersson et al., 2015). RAS mutations, possibly of prenatal origin, have been demonstrated 
also in other studies of infant leukaemia, with frequencies of 15–25 % in cases (Driessen et 
al., 2013; Prelle et al., 2013; Emerenciano et al., 2015). While the somatic dysregulation of 
RAS is a primary driver of cancer, germline mutations in genes that encode components of 
the RAS signalling pathway are involved in a number of developmental disorders (Niemeyer, 
2014). However, RAS mutations do not seem to be driver mutations in infant leukaemia, but 
instead may aid disease onset by accelerating the initial expansion of cells (Emerenciano et 
al., 2015).  
 
Overall, the activation of the RAS pathway could support the extremely rapid progression of 
infant leukaemia. Along this line, RAS activation may represent a factor modulating (i.e., 
increasing) the progression and severity of the adverse outcome, rather than a necessary key 
event (second hit) for infant leukaemia. In the transgenic MLL-AF4 mouse model, activated 
K-RAS accelerated disease onset with a short latency (Tamai et al., 2011), possibly by 
augmenting the upregulation of HoxA9. In a recent study by Prieto et al. (2016), the activated 
K-RAS enhanced extramedullary haematopoiesis of MLL-AF4-expressing cell lines and cord 
blood-derived CD34+ HSPCs, which was associated with leukocytosis and central nervous 
system infiltration. Both are hallmarks of infant MLL-AF4 leukaemia. However, K-RAS 
activation was insufficient to initiate leukaemia, supporting the involvement of the RAS 
pathway as an important modifying factor in infant leukaemia. It has also been demonstrated 
that MLL-AF6 fusion product sequesters AF6 into the nucleus to trigger RAS activation in 
myeloid leukaemia cells, which indicates that RAS may play a crucial oncogenic role in AML 
(Manara et al., 2014). The possibility that MLL fusions render cells susceptible to additional 
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chromosomal damage upon exposure to etoposide was examined by introducing MLL-AF4 
and AF4-MLL via CRISPR/Cas9-genome editing in HEK293 cells, as a model to study MLL 
fusion-mediated DNA-DSB formation/repair (Castano et al., 2016). The authors concluded 
that the expression of fusion genes does not influence DNA damage signalling or DNA-DSB 
repair. 
 
Experimental models to support the significance of rearrangements 
There are several animal models in which MLL-AF4 fusion gene has been expressed (Chen et 
al., 2006; Metzler et al., 2006; Krivtsov et al., 2008; Bursen et al., 2008; Tamai et al., 2011). 
Leukaemia is ultimately developed in all the models, but latency is very protracted (see 
Sanjuan-Pla et al., 2015). Regardless, one could conclude that the expression of the MLL-AF4 
(or its reciprocal) fusion gene in these models is capable of triggering leukaemia, but it is 
unknown whether facilitating or additional changes are required during the long latency in the 
mouse. 
 
Lin et al. (2016) designed a fusion gene between human MLL and murine af4 and 
demonstrated that it could transform–via retroviral transduction–human CD34+ cells to 
generate pro-B-ALL with all the characteristic features of the MLL-AF4 infant leukaemia. 
This finding suggests that the MLL-af4 protein retains similar molecular properties to the 
native human MLL-AF4. The authors claim that the ability of MLL-af4 to transform is due to 
the high-titre viral production. However, previous reports using MLL-AF4 also demonstrated 
proper transgene expression in CD34+ HSPCs. Therefore, this new model, despite its hybrid 
nature, offers the first real platform to experimentally study infant leukaemia.  
 
Transcription activator-like effector nuclease (TALEN)-mediated genome editing was used to 
generate endogenous MLL-AF9 and MLL-ENL oncogenes in primary human HSPCs derived 
from human umbilical cord plasma (Buechele et al., 2015). Engineered HSPCs displayed 
altered in vitro growth potential and induced acute leukaemias following transplantation in 
immunocompromised mice at a mean latency of 16 weeks. These leukaemias displayed 
phenotypic and morphologic similarities with patient leukaemia blasts, expressed elevated 
levels of crucial MLL-fusion partner target genes, displayed heightened sensitivity to DOT1L 
inhibition, and demonstrated increased oncogenic potential ex vivo and in secondary 
transplant assays. 
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Adverse Outcome (AO): Infant leukaemia 
Symptoms of leukaemia–thrombocytopaenia resulting in enhanced sensitivity to bruising and 
bleeding, anaemia with pallor and fatigue, neutropaenia associated with increased 
susceptibility to infections–are principally due to the displacement of normal haematopoiesis 
by expansion of leukaemia cells. Leukaemic infiltration of the brain is common at diagnosis 
of the infant leukaemia (Hunger and Mulligham, 2015). 
 
Clinical diagnosis is based on clinical symptoms and identification of leukaemia cells and 
altered blood cell counts by routine haematological methods. Following clinical diagnosis, 
methods for refined diagnosis include bone marrow aspirates for immunophenotypic analyses 
and cytogenetic assays for molecular stratification. Differentiation between B- and T-ALL 
and AML is of significance because particularly pro-B-ALL with the MLL-AF4 
rearrangement is the major form of infant leukaemia and its characteristics are of importance 
in judging the relevance of various experimental models for the human disease (see Lin et al., 
2016). 
 
The disease is not known in animals, and artificial animal models able to reproduce the 
disease have limitations. Bardini et al. (2015) have however developed a xenograph mouse 
model with transplanted patient MLL-AF4-involving leukoblasts. Other models developed by 
Breese et al. (2015) and Lin et al. (2016) are promising, but not yet extensively studied 
regarding their relevance. 
 
Under the OECD conceptual framework for the regulatory hazard assessment of chemicals 
with respect to mammalian toxicity, the carcinogenicity assays (OECD TG 451 and TG 453) 
and the extended one generation test (OECD TG 443) include endpoints that can potentially 
explore leukaemia as the AO; however, considerations should be made on the specificity of 
the disease to humans. 
 
Evidence for Chemical Initiation of the AOP 
The AOP conceptual framework is intended to cover only the toxicodynamic part of the 
toxicity pathway and is therefore chemically agnostic. Tool chemicals are however necessary 
to provide the empirical support for the KERs and, for this reason, identification of chemicals 
able to interact with the MIE and to trigger the pathway up to the AO is a relevant part of the 
exercise. Indeed, the greater the evidence of different chemicals activating and triggering the 
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pathway, the larger the strength of the AOP. A fairly large number of drugs, environmental 
chemicals and natural substances are identified as topo II poisons (Table 2). The anticancer 
drug etoposide has been used here as a tool chemical for building the AOP, mainly because of 
the availability and consistency of the empirical evidence. An especially interesting group is 
the bioflavonoids because they are suspected to cause infant leukaemia on the basis of 
epidemiological findings (see Hernandez and Menendez, 2015). Bioflavonoids are natural 
polyphenolic compounds in a large variety of plant-derived food items and some of them are 
used as herbal medicines. Topo II-mediated DNA cleavage has been linked to genistein, 
kaempferol, luteolin, myricetin and apigenin (Strick et al., 2000; Bandele and Osheroff, 2007; 
Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2007; Azarova et al., 2010; Lopez-
Lazaro et al., 2010), although the concentrations used in in vitro studies have been quite high. 
Several bioflavonoids are capable of inducing the cleavage of the MLL gene and producing a 
fusion gene (and its protein product) in human cell lines (Strick et al., 2000; Barjesteh van 
Waalwijk van Doorn-Khosrovani et al., 2007). The in vitro effects of bioflavonoids suggest a 
possible link between the intake of the bioflavonoid-rich diet in pregnant women and infant 
leukaemia (e.g., Azarova et al., 2010; Lanoue et al., 2010); however, epidemiological 
evidence in support of or refuting such a hypothesis is based on small studies (Ross et al., 
1996; Spector et al., 2005). 
 
Chlorpyrifos, a widely used organophosphate insecticide, and its metabolite chlorpyrifos 
oxon, have been shown to inhibit topo II activity in vitro, stabilise the topo II-DNA cleavage 
complex, cause DNA DSBs (as measured by the neutral Comet assay) and induce MLL gene 
rearrangements in human foetal liver-derived CD34+ HSPCs, as detected by FISH (Lu et al., 
2015). Accordingly, chlorpyrifos seems the most promising pesticide candidate for further in-
depth studies. Previously, Borkhardt et al. (2003) published a case study of a single preterm 
female newborn with congenital leukaemia and MLL-r whose mother had abused aerosolised 
permethrin during pregnancy because of arachnophobia. Further, incubation of permethrin in 
the BV173 cell line led to induction of MLL cleavage. Further epidemiological studies have 
found significant associations between infant leukaemia and maternal exposure to pyrethroids 
during pregnancy (Ferreira et al., 2013). 
 
Modifying conditions during the embryo-foetal period 
The available evidence suggests important differences in sensitivity to topo II inhibition 
among different cell types, depending on their inherent proliferative burden, the amount of the 
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topo II enzymes and on physiological repair processes (see Sanjuan-Pla et al., 2015). 
Mesodermal precursors and HSPCs are rapidly dividing cells with a high content of topo II 
and, for these reasons, they can be a sensitive target during a critical developmental window 
(Hernandez and Menendez, 2016). In addition, human and animal studies have found higher 
levels of DNA damage and mutations induced by mutagens in foetuses/newborns than in 
adults (Udroiu et al., 2016). For instance, micronuclei assay studies conducted in untreated 
and chemical-treated foetuses and newborns show that both the baseline and chemically-
induced micronuclei frequencies are higher in foetuses, pups and juvenile animals than in 
adults (Udroiu et al., 2016).  
 
Also, murine studies point to the life stage-related susceptibility with regard to topo II 
poisoning. Nanya et al. (2015) demonstrated that mouse foetal liver HSPCs were more 
susceptible to etoposide than maternal bone marrow mononuclear cells.    
 
The potential significance of the AOP for future research 
The major incentive to develop this AOP was epidemiological hints, that is, significant albeit 
variable associations between paediatric leukaemia and pesticide exposure (Ntzani et al 2013; 
EFSA PPR Panel 2017). Contemplating the possibilities to strengthen the epidemiology 
findings, it became obvious that a vast gap exists between wide exposure to potential topo II 
poisons and the rarity of infant leukaemia. On the basis of studies in human adult and 
paediatric leukaemia, there is a large number of genetic, epigenetic and host factors 
potentially modifying the link between various chemical exposures and leukaemia. Because 
of the rarity of the disease, it is difficult to envisage, even partially, aetiological factors as of 
importance for the infant leukaemia. 
 
In such a problematic situation, the AOP framework will serve in guiding scientific research, 
regulatory needs and testing strategy. This includes the exploration of topo II poison 
characteristics of a chemical and, if the genotoxicity standard regulatory testing battery is 
negative, considerations should be made on the sensitivity of the cell system used in the assay 
(i.e., foetal liver HSPCs). 
 
Cellular and chromosomal targets and ensuing different fusion genes 
A prerequisite for the specific outcome, that is, creation of chromosomal rearrangements, is 
that topo II inhibition and poisoning has to occur in an especially vulnerable and correct hot 
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spot in the MLL locus of target cells in order to acquire leukaemogenic potential. However, 
details of this process and how it happens are far from being fully elucidated (see Gole and 
Wiesmuller, 2015).  
 
A target cell, that is, a leukaemia-initiating cell, has not been identified with sufficient 
confidence and consequently there is no target cell model to recapitulate the linkage between 
topo II poisoning and the production of DSBs in an appropriate target. Recently, Breese et al. 
(2015) produced specific chromosomal translocations in K562 cells and in primary HSPCs by 
the expression of engineered nucleases (TALENs) to induce simultaneous DSBs and patient-
specific translocation breakpoints in the MLL gene and two different known translocation 
partners (AF4 and AF9). Lin et al. (2016) developed a model in which a rearrangement 
between human MLL and murine af4 was retrovirally transduced into HSPCs, which 
developed into leukaemic cells with similar characteristics as infant leukaemia. Comparative 
studies between various cell models should shed light on important cellular elements and 
environments conducive to leukaemogenesis. 
 
Relationships between different fusion genes and subsequent leukaemia types are 
incompletely understood. Although roughly 70–80 % of infant B-ALL carry MLL-r, the 
remaining 20–30 % of the cases lack MLL-r. In AML and T-ALL cases MLL-r are even rarer. 
Thus, it is quite possible that the AOP presented herein is strictly applicable only for the 
MLL-AF4 B cell-ALL because a fusion partner may well confer important differences in the 
execution of the leukaemogenic pathway (Marschalek, 2010). However, we believe that such 
“variations on a theme” will be within the general framework of this AOP and thus it should 
be a useful template for other closely related pathways. 
 
Animal models 
The MLL-AF4 knock-in mouse developed leukaemia only after a prolonged latency (Chen et 
al., 2006), thus not recapitulating the ‘pathognomonic’ feature of infant leukaemia. Other 
animal models have been developed with similar results (see Sanjuan-Pla et al., 2015). Thus, 
an appropriate experimental animal model for infant leukaemia is still needed. 
 
The role of a reciprocal fusion gene AF4-MLL in leukaemias is controversial. While it has 
leukaemogenic potential in animal models (Bursen et al., 2010), it is expressed only in a 
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portion of MLL-AF4 patients (Andersson et al., 2015). The potential role of other reciprocal 
fusion genes remains to be elucidated. 
 
In utero etoposide treatment of mice failed to induce leukaemogenesis (Nanya et al., 2015). 
Consequently, the envisaged linkage has not been empirically supported or rejected. 
However, it should be borne in mind that while etoposide does indeed induce a large number 
of MLL-r, most of them occur within non-coding regions and therefore do not elicit any direct 
oncogenic consequences. An MLL-AF4 in-frame fusion is a rare event that needs to occur in a 
target cell within a relatively small and spatially-restricted cell population during the 
appropriate, epigenetically plastic, developmental window. These requirements make it 
difficult to empirically support this process. 
 
Better epidemiological studies are needed 
There is limited epidemiological evidence linking pesticide exposure to infant leukaemia or 
suggesting that pesticide exposure may have a greater impact on children than adults, though 
almost all of the available evidence does not make a distinction between infant and childhood 
leukaemia. Moreover, most epidemiological studies are limited because no specific pesticides 
have been directly associated with the risk of leukaemia in children, but rather the broad term 
“pesticide exposure” (Hernandez and Menendez, 2016). A better characterisation of exposure 
is needed, particularly to identify the individual chemical (or chemical mixtures) involved, the 
level of exposure and the specific time window of exposure (whether preconceptional, 
gestational, neonatal, etc.). In this perspective, the AOP described herein would provide a 
relevant scientific and regulatory support for understanding the potential of a chemical to be 
involved in this toxicological pathway. 
 
Regulatory relevance of the AOP 
Limitations of the current regulatory guidelines regarding infant leukaemia 
Genotoxicity in general (and as a result of topo II poisoning in particular) and carcinogenicity 
are apical endpoints in established regulatory guideline studies. Topo II poisoning is one of 
the potential mechanisms of genotoxicity and carcinogenicity in various International 
Conferences on Harmonisation (ICH) guidelines for human medicines, for example, ICH M7. 
It is also known that some manifestations of genotoxicity in tests measuring chromosomal 
aberrations, micronuclei or chromosome damage (e.g., Comet assay) are partially due to 
DSBs created likely by aberrant topo II activity. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
21 
 
 
Regarding in vitro genotoxicity testing, primary cells or permanent cell lines routinely used 
for regulatory purposes may not be representative of cells in developing organisms in terms of 
sensitivity and specificity. Very early HSPCs have been considered more sensitive to 
genotoxicity because of the unfolded nature of their DNA, immature repair systems, high 
division rate, high topo II expression and activity level. Some in vivo tests, for example, the 
chromosomal aberration test and the micronucleus test, have shown a poor sensitivity, likely 
because of the low exposure of haematopoietic cells in in vivo situations. The only test 
guideline that covers the developmental period of susceptibility is the extended one-
generation test (OECD TG 443), which includes a developmental immunotoxicity cohort. At 
present, this cohort may identify postnatal effects of prenatal and neonatal exposures since 
haematology parameters and histopathology of haematopoietic organs are investigated. 
However, TG 443 has a number of limitations, including a lack of specificity to identify a 
pattern relevant to infant leukaemia in humans, and a low power due to the reduced number of 
animals examined.  
 
Regarding the carcinogenicity assay (OECD TG451 and TG453), no treatment is 
administered during the early in utero development phase, the relevant window of exposure 
for infant leukaemia. Furthermore, it should be noted that these in vivo regulatory studies, at 
their best, are designed to explore specific hazards (e.g., chemically-induced carcinogenesis), 
but not to explore complex and rare human diseases for which a more comprehensive 
scientific understanding is required for the identification of potential environmental hazards. 
Therefore, current regulatory studies have scientific limitations and experimental gaps which 
might lead to false negative results, and are thus in need of being improved for a more 
accurate hazard assessment. 
 
Advances in the understanding of physiological processes and mechanisms underlying 
diseases have not been reflected in the modification of test guidelines required for regulatory 
decision making on the approval of chemical substances. Moreover, traditional toxicology 
protocols do not incorporate data generated from emerging technologies pertaining to 
molecular mechanisms and signalling pathways. Since regulatory decisions should be based 
on the best available science, more predictive, reliable, faster and less expensive approaches 
are needed to provide mechanism-based, chemical-specific toxicity information to inform 
more reliably human health risk assessment.  
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In Fig 3, we have outlined a larger framework–an Integrated Approach to Testing and 
Assessment (IATA)–into which the current AOP would fit as an integral part (Tollefsen et al., 
2014). If the existing information, also including experimental research within the IATA 
framework, allows the regulatory decision to be made, there is no urgent need to perform 
additional experiments. However, if the weight of evidence assessment indicates that the 
information is inadequate for decision making, generation of new data based on the AOP 
assays is seen as advisable, followed by a new round of weight of evidence assessment. In this 
way, only targeted studies could be performed and evaluated under the IATA framework. The 
proposed IATA would rely not solely on data from regulatory and/or experimental animal 
studies, but rather on mechanistic understanding and on specific problem formulation. 
Accordingly, regulatory decision-making would also take into account other data, such as in 
silico, in chemico and in vitro data, to complement the traditional regulatory data, and the 
decision making would be tailored to the problem formulation and allowing data gaps to be 
identified. To help the regulatory scientist in building confidence in data from such tools and 
their associated predictive models, these new data need to be characterised and qualified. A 
systematic evaluation of the AOP as well as AOP-informed IATA according to Patlewitz et 
al. (2015) is recommended.   
 
CONCLUSIONS 
The AOP described herein was developed with the intention to use an epidemiologically-
based human health outcome as AO, and then build back an AOP leading to this AO. Infant 
leukaemia is a human disease and consequently apical regulatory endpoints explored by the 
experimental toxicological studies, can at their best explore the hazard only by means of 
surrogate testing. These include genotoxicity and carcinogenesis assays and blood cell 
analyses in the in vivo toxicology assessment. Considering the unique biology of this AO, 
these tests present some scientific and technical limitations as well as a lack of sufficient 
sensitivity and specificity for the AO. Additionally, experimental animal models replicating 
the AO are limited. Technical limitations of the current regulatory tests include the following: 
standard carcinogenesis studies do not include an early in utero exposure time window, blood 
cell analysis is not a standard requirement in the extended one-generation reproductive 
toxicity study, and no cancer-related endpoints are included in this study. In addition, 
considering the rarity and the complexity of the disease, the sensitivity and specificity of the 
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regulatory tests to capture this hazard is likely to be a big hurdle, such that they are unlikely to 
represent the best way to explore this AO. In addition, some evidence indicates that the 
current genotoxicity testing battery lacks sufficient sensitivity and specificity to capture the 
essential KE, MLL-r, and comparative testing for chromosome translocation/aberration 
between standard cell systems and HSPCs should be a matter of additional research. The AOP 
described herein clearly indicates that the MIE and the KE1 can be measured in scientific 
and/or regulatory validated test assays.  
 
With the above premises, the authors support the use of this AOP during the process of 
assessment of epidemiological studies and the utilisation of the AOP framework to support 
the biological plausibility of the effects observed in the epidemiological studies when 
experimental and toxicological studies indicate that the AOP is affected. The AOP conceptual 
framework should also inform IATA as part of a compound specific risk assessment and 
guide on which additional studies should be possibly performed, if the case, to fulfil data gaps 
and integrate the AOP into the mode of action (MOA) framework.  
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LEGENDS TO THE FIGURES 
 
Fig 1 The developed scheme for the Adverse Outcome Pathway (AOP): In utero DNA 
topoisomerase II poisoning leading to infant leukaemia. 
 
Fig 2 A schematic view of molecular and biochemical processes distal from MLL fusion gene 
formation. MLL-fusion protein-containing chromatin modifying complex binds histone 
methyltransferases, which through histone methylation activate various target genes (HOXA 
cluster, MEIS1, BCL-2, etc), which cause differentiation block, maintain survival and provide 
proliferative advantage for MLL-rearranged leukaemia cells (see Marschalek, 2010, Ballabio 
and Milne, 2012, 2014; Sanjuan-Pla et al., 2015; Benito et al., Cell Rep 2015). It is probable 
that other fusion proteins activate an analogous chain of events, which leads to similar 
outcomes. 
 
Fig 3 Example of the AOP informed IATA for Infant Leukaemia. The goal is to take into 
consideration all the available information and continue along the weight of evidence 
assessment for the need of generating new information based on the infant leukaemia AOP 
assays. 
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Table 1. Comparison of some characteristics of infant, childhood and treatment-related adult acute 
leukaemia (see reviews of Cowell and Austin, 2012; Ezoe, 2012; Pendleton and Osheroff, 2014; 
Sanjuan-Pla et al., 2015; Gole and Wiesmuller, 2015) 
 
Characteristic Infant leukaemia 
(esp. MLL-AF4) 
Childhood 
leukaemia 
Treatment 
(etoposide)-related 
acute leukaemia 
Incidence (cases per 
106 newborns) 
1? 40? <10 % of the treated 
patients on particular 
anticancer regimens 
(see table 2) 
Incidence peak 
(years of age) 
<1 3–5 within 2 years after 
the onset of treatment 
First “hit” in utero in utero? soon after the onset 
of treatment 
Second “hit” probably not needed in utero/postnatal probably not needed 
Latency short long short 
Prognosis (5-yr) poor (38%) good (80%) poor 
Principal 
rearrangement 
MLL-AF4 (about 
60–80% of ALL) 
TEL-AML1 
HYPERDIPLOID 
BCR-ABL 
E2A-PBX1 
(MLL-AF4 3%) 
MLL-AF4 (about 
40% of t-AL), 
PML-RARA in acute 
pro-myelocytic 
leukaemia by esp. 
mitoxantrone 
Distribution of break 
sites at bcra 
telomeric centromeric and 
telomeric 
telomeric 
Phenotypic 
characteristics 
Pro-B/mixed: 
lymphoid CD34+, 
CD19+, CD10-; 
myeloid CD15+, 
CD65+ and NG2+ 
variable; mostly B-
ALL but also AML 
and T-lymphoid-
ALL 
Mostly myeloid 
 
abcr, breakpoint cluster region of the MLL gene (between exon 8 and intron 10/exon 11) 
  
Table
Table 2. The most frequent partners in the infant leukaemia-associated MLL gene rearrangement 
products (Marschalek, 2010) 
Fusion partner  Structural features Functional features 
MLL (KMT2A) lysine methyltransferase 2A 
PHD finger protein 
zinc finger CXXC-type 
MLL complex: chromatin 
activation, cell cycle control, 
DNA repair 
MLL•AF4 leukaemogenic 
AF4 (AFF1) super elongation complex AF4•MLL leukaemogenic 
AF6 (AFDN, MLLT4) adherens junction formation 
factor, PDZ domain protein 
? 
AF9 (MLLT3) super elongation complex 
subunit 
? 
AF10 (MLLT10) PHD finger protein ? 
ENL (MLLT1) super elongation complex 
subunit 
? 
 
 
Table 3. Chemicals identified as DNATopoisomerase II poisons 
Chemical class and chemicals Positive findings in vitro and in vivo References (and remarks) 
Anticancer agents* (see Cowell and Austin, 2012) 
Epipodophyllotoxins 
etoposide 
 
teniposide 
 
Topo II poison in vitro, leukaemogenic in vivo 
in humans (therapy-associated AL) 
by analogous mechanism of action 
Ezoe, 2012; Montecucco et al., 2015 
‘Tool chemical’ for developing the AOP 
 
in combination treatment regimens 
Anthracyclines 
doxorubicin 
 
MLL breakpoint detection  (Thys et al 2015) 
Cowell and Austin, 2012 
in combination treatment regimens 
Bioflavonoids (see Ketron and Osheroff 2014) 
Flavones 
luteolin, apigenin, diosmetin 
 
Topo II DNA cleavage and MLL 
rearrangement in vitro 
 
Strick et al., 2000; Bandele and Osheroff, 2007 
Flavonols 
myricetin, quercetin, 
kaempferol, fisetin 
 
Topo II DNA cleavage and MLL 
rearrangement in vitro and in vivo 
 
Strick et al., 2000; Bandele and Osheroff, 2007; 
Vanhees et al., 2011 
Isoflavones 
Genistein 
(daidzein, biochanin A inactive) 
 
 
Topo II DNA cleavage and MLL 
rearrangement in vitro and in vivo  
 
Strick et al., 2000; Bandele and Osheroff, 2007; 
Barjesteh van Waalwijk van Doorn-Khosrovani et 
al., 2007; Azarova et al., 2010; Vanhees et al., 2011 
Catechins** Topo II cleavage  Austin et al., 1992; Bandele et al., 2008 
Isothiocyanates*** Topo II cleavage Lin et al., 2014 
Curcumin Topo II cleavage and MLL rearrangements Lopez-Lazaro et al., 2007; Ketron et al., 2013 
Environmental chemicals 
Benzene MLL breakpoint detection Thys et al., 2015 
Diethylnitrosamine MLL breakpoint detection Thys et al., 2015 
Chlorpyrifos MLL rearrangements in human cells Lu et al., 2015 
Permethrin MLL cleavage in cell culture Borkhardt et al., 2003 
 
*anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin, aclarubicin), anthracenediones (mitoxantrone) and acridines (amsacrine) differ from epipodophyllotoxins 
in that in addition to topo II poisoning, they have other mechanisms of action leading to cytotoxicity (Cowell and Austin, 2012). Except for doxorubicin and mitoxanthrone, 
other drugs in these classes have not been specifically studied regarding MLL rearrangements. 
**for example EGCG (epigallocatechin gallate) and EGC (epigallocatechin) are very strong topo II poisons in vitro, but ECG (epicatechin gallate) and (EC (epicatechin) 
inactive) are virtually inactive. 
***benzyl-isothiocyanate, phenethyl-isothiocyanate, sulforaphane. 
